Table of Contents Author Guidelines Submit a Manuscript
Journal of Oncology
Volume 2010, Article ID 934359, 5 pages
http://dx.doi.org/10.1155/2010/934359
Review Article

CoFactor: Folate Requirement for Optimization of 5-Fluouracil Activity in Anticancer Chemotherapy

1Clinical Medicine, The GI Oncology Section of the Division of Hematology/Oncology, Herbert Irving Comprehensive Cancer Center, Columbia University College of Physicians and Surgeons, Milstein Hospital, 177 Fort Washington Avenue, Suite 6-435, NY 10032, USA
2Oncology Unit, Third Department of Medicine, Sotiria General Hospital, Athens Medical School, Mesogion 152, Athens 11527, Greece

Received 12 September 2010; Revised 2 November 2010; Accepted 8 November 2010

Academic Editor: Dominic Fan

Copyright © 2010 Muhammad Wasif Saif et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. V. Danenberg, “Pharmacogenomics of thymidylate synthase in cancer treatment,” Frontiers in Bioscience, vol. 9, pp. 2484–2494, 2004. View at Google Scholar · View at Scopus
  2. M. P. Costi, S. Ferrari, A. Venturelli, S. Calò, D. Tondi, and D. Barlocco, “Thymidylate synthase structure, function and implication in drug discovery,” Current Medicinal Chemistry, vol. 12, no. 19, pp. 2241–2258, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. E. Di Gennaro, F. Bruzzese, S. Pepe et al., “Modulation of thymidilate synthase and p53 expression by HDAC inhibitor vorinostat resulted in synergistic antitumor effect in combination with 5FU or raltitrexed,” Cancer Biology and Therapy, vol. 8, no. 9, pp. 782–791, 2009. View at Google Scholar · View at Scopus
  4. A. Lockshin and P. V. Danenberg, “Biochemical factors affecting the tightness of 5-fluorodeoxyuridylate binding to human thymidylate synthetase,” Biochemical Pharmacology, vol. 30, no. 3, pp. 247–257, 1981. View at Publisher · View at Google Scholar · View at Scopus
  5. C. P. Spears, A. A. Hayes, A. H. Shahinian, P. V. Danenberg, R. Frosing, and B. G. Gustavsson, “Deoxyuridylate effects on thymidylate synthase-5-fluorodeoxyuridylate-folate ternary complex formation,” Biochemical Pharmacology, vol. 38, no. 18, pp. 2985–2993, 1989. View at Publisher · View at Google Scholar · View at Scopus
  6. C. W. Carreras and D. V. Santi, “The catalytic mechanism and structure of thymidylate synthase,” Annual Review of Biochemistry, vol. 64, pp. 721–762, 1995. View at Google Scholar · View at Scopus
  7. Y. M. Rustum, “Thymidylate synthase: a critical target in cancer therapy?” Frontiers in Bioscience, vol. 9, pp. 2467–2473, 2004. View at Google Scholar · View at Scopus
  8. F. Wohlrab, T. Haertle, T. Trichtinger, and W. Guschlbauer, “2 Deoxy 2 fluorouridine 5 phosphate: an alternative substrate for thymidylate synthetase from Escherichia coli K12,” Nucleic Acids Research, vol. 5, no. 12, pp. 4753–4759, 1978. View at Google Scholar · View at Scopus
  9. C. P. Spears, G. Carlsson, F. M. Muggia, G. Jaresko, and B. G. Gustavsson, “Aspects of one-carbon folate cycling related to fluoropyrimidine and antifolate therapy,” Cancer treatment and research, vol. 78, pp. 115–134, 1995. View at Google Scholar · View at Scopus
  10. C. Underhill, D. Goldstein, V. A. Gorbounova et al., “A randomized phase II trial of pemetrexed plus irinotecan (ALIRI) versus leucovorin-modulated 5-FU plus irinotecan (FOLFIRI) in first-line treatment of locally advanced or metastatic colorectal cancer,” Oncology, vol. 73, no. 1-2, pp. 9–20, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Novarino, M. A. Satolli, I. Chiappino et al., “Oxaliplatin, 5-fluorouracil, and leucovorin as second-line treatment for advanced pancreatic cancer,” American Journal of Clinical Oncology: Cancer Clinical Trials, vol. 32, no. 1, pp. 44–48, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. I. Popov, A. Carrato, A. Sobrero et al., “Raltitrexed (Tomudex) versus standard leucovorin-modulated bolus 5-fluorouracil: results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1),” European Journal of Cancer, vol. 44, no. 15, pp. 2204–2211, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. A. Strohle, M. Wolters, and A. Hahn, “Folic acid and colorectal cancer prevention: molecular mechanisms and epidemiological evidence (Review),” International Journal of Oncology, vol. 26, no. 6, pp. 1449–1464, 2005. View at Google Scholar · View at Scopus
  14. S. Sadahiro, T. Suzuki, Y. Maeda et al., “Molecular determinants of folate levels after leucovorin administration in colorectal cancer,” Cancer Chemotherapy and Pharmacology, vol. 65, no. 4, pp. 735–742, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. S. Marsh and H. L. McLeod, “Thymidylate synthase pharmacogenetics in colorectal cancer,” Clinical Colorectal Cancer, vol. 1, no. 3, pp. 175–179, 2001. View at Google Scholar · View at Scopus
  16. T. Gangadhar and R. L. Schilsky, “Molecular markers to individualize adjuvant therapy for colon cancer,” Nature Reviews Clinical Oncology, vol. 7, no. 6, pp. 318–325, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. J. R. Bertino, “Cancer research: from folate antagonism to molecular targets,” Best Practice and Research: Clinical Haematology, vol. 22, no. 4, pp. 577–582, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. C. P. Spears, “Clinical resistance to antimetabolites,” Hematology/Oncology Clinics of North America, vol. 9, no. 2, pp. 397–413, 1995. View at Google Scholar · View at Scopus
  19. B. A. Jennings, G. A. Willis, J. Skinner, and C. L. Relton, “Genetic selection? A study of individual variation in the enzymes of folate metabolism,” BMC Medical Genetics, vol. 11, no. 1, article 18, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. Y. G. Assaraf, “Molecular basis of antifolate resistance,” Cancer and Metastasis Reviews, vol. 26, no. 1, pp. 153–181, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. K. L. Seley, “Cofactor biokeys pharmaceuticals,” IDrugs, vol. 4, no. 1, pp. 99–101, 2001. View at Google Scholar · View at Scopus
  22. S. K. Bjelogrlić, T. Srdić, and S. Radulović, “Comparison between CoFactor and Leucovorin activity applied in combination with 5-fluorouracil against two human colon cancer cell lines,” Journal of B.U.ON., vol. 12, no. 1, pp. 71–76, 2007. View at Google Scholar · View at Scopus
  23. M. J. Cantwell and J. Robbins, “5,10-methylenetetrahydrofolate/5-fluorouracil combination therapy shows enhanced antitumor activity and lower systemic toxicity with a broad range of cytotoxic drugs,” Proceedings of the American Association for Cancer Research, vol. 46, abstract 5107, 2005. View at Google Scholar
  24. M. J. Cantwell, C. P. Spears, and J. Robbins, “Antitumor activity of combination 5,10-methylenetetrahydrofolate, 5-fluorouracil, and anti-vascular endothelial growth factor against human colorectal HT-29 tumors in nude mice,” Journal of Clinical Oncology, vol. 22, no. 14S, p. 3768, 2004. View at Google Scholar
  25. G. Carlsson, E. Odin, P. A. Larsson, R. Frosing, C. P. Spears, and B. Gustavsson, “Phase I-II study of weekly 5-fluorouracil and 5,10-methylene- tetrahydrofolate in patients with advanced gastrointestinal and breast cancer,” Cancer Journal, vol. 10, no. 5, pp. 266–273, 1997. View at Google Scholar · View at Scopus
  26. T. Reid, C. P. Spears, R. Quadro et al., “5,10-methylenetetrahydrofolic acid with 5-fluorouracil as first line treatment in metastatic colorectal cancer: phase II study results,” Journal of Clinical Oncology, vol. 24, no. 18S, p. 3599, 2006. View at Google Scholar
  27. T. Reid, C. Spears, M. Subramanian et al., “Response to second line treatment following 5,10-methylenetetrahydropholic acid with 5-fluorouracil as first line treatment in metastatic colorectal cancer,” Annals of Oncology, vol. 17, supplement 6, pp. vi32–vi108, 2006. View at Google Scholar
  28. C. L. Costantini, T. R. Reid, and M. Bouvet, “Resection of hepatic metastasis after 5-fluorouracil and CoFactor for colon cancer,” Hepato-Gastroenterology, vol. 56, no. 91-92, pp. 645–649, 2009. View at Google Scholar · View at Scopus
  29. US National Institutes of Health, http://www.clinicaltrials.gov/ct2/show/NCT00235898?term=CoFactor&rank=5.
  30. M. W. Saif, Manges, C. Redfern et al., “Comparative Clinical Trial to evaluate the Safety and efficacy o coFactor (CF) and 5-Fluouracil (FU) plus Bevacizumab (BV) versus Leucovorin (LV) and FU plus BV in patients with Metastatic Colorectal carcinoma,” Annals of Oncology, vol. 19, supplement 8, pp. viii125–viii152, abstract 444, 2008. View at Google Scholar
  31. US National Institutes of Health, http://www.clinicaltrials.gov/ct2/show/NCT00337389?term=CoFactor&rank=2.
  32. J. Stewart, G. Berman, V. F. Semiglazov et al., “5,10 methylenetetrahydrofolic acid with fluorouracil as treatment for advanced breast cancer in patients who failed prior treatment with anthracyclines and taxanes: a phase II study,” Journal of Clinical Oncology, vol. 26, no. 15S, p. 1136, 2008. View at Google Scholar
  33. “ADVENTRX Receives CoFactor Pancreatic Cancer Clinical Design and Protocol Final Advice Letter from EMEA,” http://ir.adventrx.com/phoenix.zhtml?c=75414&p=irol-newsArticle&ID=773312&highlight=.